Solid tumor/s, Cancer, Castration-resistant prostate cancer
MGNXMacroGenicsCatalyst overview
Research summary
This catalyst tracks a Failed discontinued for Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel in Solid tumor/s, Cancer, Castration-resistant prostate cancer. The expected timing is based on the latest available company guidance and may change.
LORIKEET study. Trial initiated. 5/9/24 Complete enrollment in 2024. 5/13/25- Clinical update in H2 2025. 11/12/25:- Company determined that lorigerlimab plus docetaxel and prednisone in second-line mCRPC will not meet the LORIKEET Phase 2 trial primary endpoint and has stopped further development in prostate cancer, although final data will be presented or published at a later date.
Verification
Confirm timing and program details against the company announcement or filing.